Recent data from the European Randomized Screening for Prostate Cancer Trial suggest that many of these cases pose little threat of disease progression and that only 1 of every 37–48 men diagnosed by PSA testing may benefit from aggressive treatment (Roobol et al, 2009). Here, KLK3 is linked to prostate cancer.